Literature DB >> 20713354

Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice.

Dan Li1, Duan Wang, Yun Wang, Wenhua Ling, Xiang Feng, Min Xia.   

Abstract

Increasing evidence suggests that adenosine monophosphate-activated protein kinase (AMPK) exerts protective effects for cardiovascular diseases apart from the regulation of energy homeostasis. However, the role of AMPK and its underlying mechanism on macrophage foam cell formation are poorly understood. In this study, we sought to investigate the potential effects of AMPK in modulating cholesterol deposition by using murine macrophage-derived foam cells. Incubation with 5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR) markedly attenuated the cholesterol ester accumulation in oxidized low density lipoprotein-loaded macrophages. Notably, AICAR treatment significantly increased ATP-binding cassette transporters G1 (Abcg1) mRNA and protein levels without affecting mRNA and protein expression of ABCA1, scavenger receptors, including scavenger receptor-A, CD36, and scavenger receptor-BI (SR-BI), and cholesterol synthesis-related genes. The up-regulation of Abcg1 by AICAR was independent of the liver X receptor/retinoid X receptor pathway but dependent on ERK activation. AICAR elevates Abcg1 expression through a post-transcriptional mechanism that stabilizes the mRNA. Using a heterologous system with luciferase as a reporter, we further identify the Abcg1 mRNA 3'-UTR responsible for the regulatory effect of AICAR. Prevention of ABCG1 expression by small interfering RNA abolished the AICAR-mediated attenuation on foam cell formation. Furthermore, increased ABCG1 expression and reduced lipid accumulation were demonstrated in AICAR-treated macrophages isolated from apolipoprotein E-deficient mice (apoE(-/-) mice). AICAR treatment also inhibited atherosclerotic plaque formation in apoE(-/-) mice. Our findings elucidate a precise mechanism involved in the prevention of atherogenesis by AMPK.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713354      PMCID: PMC2963409          DOI: 10.1074/jbc.M110.159772

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  Atherosclerosis. the road ahead.

Authors:  C K Glass; J L Witztum
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 2.  Messenger RNA regulation: to translate or to degrade.

Authors:  Ann-Bin Shyu; Miles F Wilkinson; Ambro van Hoof
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

3.  Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction.

Authors:  Eberhard Schulz; Jörn Dopheide; Swenja Schuhmacher; Shane R Thomas; Kai Chen; Andreas Daiber; Philip Wenzel; Thomas Münzel; John F Keaney
Journal:  Circulation       Date:  2008-09-23       Impact factor: 29.690

4.  ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein.

Authors:  N Wang; D L Silver; C Thiele; A R Tall
Journal:  J Biol Chem       Date:  2001-04-17       Impact factor: 5.157

5.  Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice.

Authors:  V R Babaev; M B Patel; C F Semenkovich; S Fazio; M F Linton
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

6.  Adenosine monophosphate activated protein kinase regulates ABCG1-mediated oxysterol efflux from endothelial cells and protects against hypercholesterolemia-induced endothelial dysfunction.

Authors:  Dan Li; Yuan Zhang; Jing Ma; Wenhua Ling; Min Xia
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-15       Impact factor: 8.311

7.  PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

Authors:  G Chinetti; S Lestavel; V Bocher; A T Remaley; B Neve; I P Torra; E Teissier; A Minnich; M Jaye; N Duverger; H B Brewer; J C Fruchart; V Clavey; B Staels
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

Review 8.  Atherosclerosis.

Authors:  A J Lusis
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

9.  High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1.

Authors:  J McNeish; R J Aiello; D Guyot; T Turi; C Gabel; C Aldinger; K L Hoppe; M L Roach; L J Royer; J de Wet; C Broccardo; G Chimini; O L Francone
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

10.  Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways.

Authors:  Keun-Gyu Park; Ae-Kyung Min; Eun Hee Koh; Hyoun Sik Kim; Mi-Ok Kim; Hye-Sun Park; Yong-Deuk Kim; Tae-Seung Yoon; Byoung Kuk Jang; Jae Seok Hwang; Jae Bum Kim; Hueng-Sik Choi; Joong-Yeol Park; In-Kyu Lee; Ki-Up Lee
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

View more
  35 in total

1.  Novel Role of miR-33 in Regulating of Mitochondrial Function.

Authors:  Nathan L Price; Carlos Fernández-Hernando
Journal:  Circ Res       Date:  2015-07-17       Impact factor: 17.367

2.  Activation of AMP-activated protein kinase inhibits the proliferation of human endothelial cells.

Authors:  Kelly J Peyton; Xiao-ming Liu; Yajie Yu; Benjamin Yates; William Durante
Journal:  J Pharmacol Exp Ther       Date:  2012-06-13       Impact factor: 4.030

3.  Tissue cholesterol content alterations in streptozotocin-induced diabetic rats.

Authors:  Xin-ting Wang; Jia Li; Li Liu; Nan Hu; Shi Jin; Can Liu; Dan Mei; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2012-06-18       Impact factor: 6.150

Review 4.  Practical strategies for modulating foam cell formation and behavior.

Authors:  Elisabeth Uitz; Babak Bahadori; Mark F McCarty; Mohammed H Moghadasian
Journal:  World J Clin Cases       Date:  2014-10-16       Impact factor: 1.337

5.  AMPKα2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6.

Authors:  Brendan Gongol; Traci Marin; I-Chen Peng; Brian Woo; Marcy Martin; Stephanie King; Wei Sun; David A Johnson; Shu Chien; John Y-J Shyy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

6.  Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy.

Authors:  Chuanrui Ma; Wenwen Zhang; Xiaoxiao Yang; Ying Liu; Lipei Liu; Ke Feng; Xiaomeng Zhang; Shu Yang; Lei Sun; Miao Yu; Jie Yang; Xiaoju Li; Wenquan Hu; Robert Q Miao; Yan Zhu; Luyuan Li; Jihong Han; Yuanli Chen; Yajun Duan
Journal:  Br J Pharmacol       Date:  2018-03-23       Impact factor: 8.739

7.  Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice.

Authors:  LinZhang Huang; BaoYan Fan; Ang Ma; Philip W Shaul; HaiBo Zhu
Journal:  J Lipid Res       Date:  2015-03-11       Impact factor: 5.922

Review 8.  AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases.

Authors:  Rai Ajit K Srivastava; Stephen L Pinkosky; Sergey Filippov; Jeffrey C Hanselman; Clay T Cramer; Roger S Newton
Journal:  J Lipid Res       Date:  2012-07-13       Impact factor: 5.922

Review 9.  AMPK activation--protean potential for boosting healthspan.

Authors:  Mark F McCarty
Journal:  Age (Dordr)       Date:  2013-11-19

Review 10.  AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System.

Authors:  Ian P Salt; D Grahame Hardie
Journal:  Circ Res       Date:  2017-05-26       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.